Agios Pharmaceuticals | AGIO - Pre Tax Profit


Agios Pharmaceuticals reported $-99.11M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
Astellas Pharma JPY 48.02B 85.93B Mar/2026
AstraZeneca USD 3.91B 1.28B Mar/2026
Bayer EUR -3.37B 2.21B Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Exelixis USD 267.69M 15M Mar/2026
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Incyte USD 343.6M 46.34M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Moderna USD -799M 612M Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Novartis USD 3.84B 802M Mar/2026
Novartis USD 3.84B 1.33B Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026